title: Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.
authors.affiliation: University Medical Center, Eijkman Winkler Institute, Department of Virology, Utrecht, Netherlands.
authors.forename: Inge
authors.initials: I
authors.lastname: Derdelinckx
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wainberg
authors.forename: Joep M A
authors.initials: JM
authors.lastname: Lange
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Halima
authors.forename: Charles A B
authors.initials: CA
authors.lastname: Boucher
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000191:economics / Q000592:standards* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D012107:Research Design
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D004338:Drug Combinations; D019259:Lamivudine